Abstract:Gerhard Hamilton, Adelina Plangger Department of Vascular Surgery, Medical University of Vienna, Vienna, Austria Correspondence: Gerhard Hamilton Department of Vascular Surgery, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria Tel +43-1-40400 Email Lung cancer has a dismal prognosis and novel targeted therapies leave still room for major improvements and better outcomes. Immunotherapy targeting immune checkpoint (IC) proteins, either as single agents or in combination with chemotherapy, is active but responders constitute only approximately 10– 15% of non-small cell lung cancer (NSCLC) patients. Other effector immune cells such as CAR-T cells or NK cells may help to overcome the limitations of the IC inhibitor therapies for lung cancer. NK cells can kill tumor cells without previous priming and are present in the circulatory system and lymphoid organs. Tissue-residing NK cells differ from peripheral effector cells and, in case of the lung, comprise CD56bright CD16-negative populations showing high cytokine release but low cytotoxicity in contrast to the circulating CD56dim CD16-positive NK cells exhibiting high cytotoxic efficacy. This local attenuation of NK cell killing potency seems due to a specific stage of NK differentiation, immunosuppressive factors as well as presence of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (TREGs). Improved NK cell-based immunotherapies involve IL-2-stimulated effector cells, NK cells expanded with the help of cytokines, permanent NK cell lines, induced pluripotent stem cell-derived NK cells and NK cells armed with chimeric antigen receptors. Compared to CAR T cell therapy, NK cells administration is devoid of graft-versus-host disease (GvHD) and cytokine-release syndrome. Although NK cells are clearly active against lung cancer cells, the low-cytotoxicity differentiation state in lung tumors, the presence of immunosuppressive leucocyte populations, limited infiltration and adverse conditions of the microenvironment need to be overcome. This goal may be achieved in the future using large numbers of activated and armed NK cells as provided by novel methods in NK cell isolation, expansion and stimulation of cytotoxic activity, including combinations with monoclonal antibodies in antibody-dependent cytotoxicity (ADCC). This review discusses the basic characteristics of NK cells and the potential of NK cell preparations in cancer therapy. Keywords: natural killer cells, immunotherapy, chimeric antigen receptor, antibody-dependent cytotoxicity, lung cancer, interleukins Lymphoid non-T cells that can kill virally infected and tumor cells were described more than four decades ago and termed natural killer (NK) cells. 1 NK cells can attack tumor cells without priming and their activity depends on a range of stimulatory and inhibitory receptors. 2 , 3 NK cells comprise about 5–15% of the human peripheral blood mononuclear cells (PBMCs) and are part of the native immune system that screen cell membranes of autologous cells for a reduced expression of MHC class I molecules and increased expression of cell stress markers. 4 , 5 NK cells mediate the direct and rapid killing of freshly isolated human cancer cells from hematopoietic and solid tumors. 6 , 7 ( Figure 1 ) NK cells in human peripheral blood, bone marrow and various tissues are characterized by the absence of T cell receptors (TCR) and the corresponding CD3 molecules as well as by the expression of neural cell adhesion molecule (NCAM/CD56). 8 Human NK cells are generated from multilineage CD34+ hematopoietic progenitors in the bone marrow and their maturation occurs at this site of origin as well as in the lymphoid organs but not in thymus. 9 In blood, NK cells show a turnover time of approximately 2 weeks with a doubling within 13.5 days in vivo and in vitro cytokine stimulation of peripheral blood NK cells can result in expansion with a median of 16 (range 11–30) population doublings. 10 Figure 1 NK cells and other immune cells in the tumor microenvironment. NK cells of the CD56dim CD16+ phenotype secrete interferon-γ (IFN-γ), which increases the expression of MHC class I of tumor cells, enhancing the presentation of tumor antigens to T cells. Inhibitory checkpoint molecules expressed by NK cells can be blocked using specific monoclonal antibodies (ICIs). NK cells of the CD56bright CD16- phenotype recruit dendritic cells (DCs) to the tumor microenvironment (TME) and drive their maturation via chemokine ligands CCL5, XCL1 and FMS-related tyr -Abstract Truncated-

Tumor-Localization By Adoptively Transferred, Interleukin-2-Activated Nk Cells Leads To Destruction Of Well-Established Lung Metastases

Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases

Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.

Activated Mouse CD4+Foxp3- T Cells Facilitate Melanoma Metastasis Via Qa-1-dependent Suppression of NK Cell Cytotoxicity (127.17)

Cytokine Gene Therapy Using Adenovirally Transduced, Tumor-Seeking Activated Natural Killer Cells.

Primary Tumors Limit Metastasis Formation through Induction of IL15-Mediated Cross-Talk between Patrolling Monocytes and NK Cells

Adoptive Transfer of Tumor Reactive B Cells Confers Host T-cell Immunity and Tumor Regression.

Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors

Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases

Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.

Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells

Improved Antitumor Effect of NK Cells Activated by Neutrophils in a Bone Marrow Transplant Model

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells

Abstract 4158: Selective targeting of CD122 combined with radiotherapy triggers CD8 and NK mediated immunity, abrogating metastasis in head and neck squamous cell carcinoma

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity

Development of adoptive immunotherapy with KK-LC-1-specific TCR-transduced γδT cells against lung cancer cells

Attribution Of Nkg2dl To The Inhibition Of Early Stage Allogeneic Tumors In Mice

Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.

Adoptive Transfer of Natural Killer Cells in Combination with Chemotherapy Improves Outcomes of Patients with Locally Advanced Colon Carcinoma.

The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy